Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).

Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019 Nov 21;: Authors: Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N Abstract Chimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well as relapsed/refractory Diffuse Large B-cell Lymphoma; Axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. Both agents are genetically engineered autologous T-cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research

Related Links:

Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually relapse. Relapse or non-response to CD19-directed CAR therapy may be due to low or diminished CD19 expression. Such patients would be predicted to benefit from CAR therapies targeting other B-cell surface proteins, such as CD22.Scientists at the National Cancer Institute ’s (NCI) Pe...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
ConclusionThe use of pediatric-inspired protocol for high risk AYA ALL was effective and well tolerated with improvement in OS and DFS compared to historical data using adult protocols in such population
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study included 18 buffy coats collected from volunteer blood donors admitted to the blood transfusion service of IRCCS Bambino Gesù Pediatric Hospital after obtaining informed consent. The Ethical Committee of IRCCS Bambino Gesù Pediatric Hospital approved the study (825/2014) and conducted in accordance with the ethical principles stated in the Declaration of Helsinki. Cells Lines and Cell Culture NK-92 (malignant non-Hodgkin's lymphoma), K562 (chronic myelogenous leukemia, CD19−), Jurkat (acute T cell leukemia, CD19−) Karpas 299 (Human Non-Hodgkin's Ki-positive Large Cell ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions The discovery of JAK2V617F mutation in BCR-ABL1-negative MPNs by four different international cooperative groups in 2005 (2–5) led to significant insights on the pathogenesis of these disorders. In fact, this mutation results in a gain-of-function with activation of cytokine and growth factor receptors, and thus of the downstream JAK-STAT pathway (79, 95–98). The JAK2 point mutation in exon 12, present in a small percentage of patients with PV, is able to induce the MPN phenotype through the same pathogenic mechanism (6, 7). In 2006 the MPLW515L/K was reported in ET and PMF patients (44, 45) and d...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study proposed a pilot study of a new tool for a reliable and accurate stratification of patients with acute leukemia based on an integrative model of leukemia behavior, cell characterization, and clinical features, in addition, to an evaluation of intra-tumor and inter-tumor heterogeneity. Together our approach allows us to introduce an integrative quantitative approach to use zebrafish and tumor characterization as a prediction tool for the behavior of acute leukemia in young adults. Materials and Methods Animal Care and Handling Zebrafish wild-type (A/B and TAB5) adults were raised and maintained according to st...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
B-lymphoblastic leukemia/lymphoma (B-ALL) BCR-ABL1-like (Ph-like) is a provisional entity in the 2016 revision of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. The incidence of Ph-like ALL is 15-30% in children and young adults with B-ALL. Genetic abnormalities associated with Ph-like ALL are heterogenous. Approximately 50% of Ph-like ALL patients may have cytokine receptor like factor 2 (CRLF2) gene overexpression, JAK2 mutations with activation of JAK-STAT pathway and a poor clinical outcome.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was approved by the FDA in 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL), as well as adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer. Since the CAR-T modified cells multiply and persist in the patient's bloodstream, they have the potential to protect the patient against recurrence.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 501 Source Type: research
Conclusions: We report a high rate of guideline-driven care for AYAs with acute leukemia and lymphoma seen by a multidisciplinary team solely focused on AYA care delivery within a community practice setting. Metrics are derived from best practices from both pediatric (pediatric inspired therapy in AML, ALL; sedation for procedures) and adult (ABVD for HL, NCI and pharma-sponsored trials) oncology paradigms. Immersive AYA programs in non-academic settings are potentially effective models of reducing health disparities and improving outcomes in AYAs.Table 1.DisclosuresCrosswell: Seattle Genetics: Other: stock ownership in Seattle Genetics.
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Poster III Source Type: research
AbstractHistorically, adolescents and young adults (AYA) diagnosed with cancer have been an understudied population, and their unique care experiences, needs, and outcomes were not well understood. Thus, 10 years ago, the National Cancer Institute supported the fielding of the Adolescent and Young Adult Health Outcomes and Patient Experiences (AYA HOPE) study to address this gap. We recruited individuals diagnosed at ages 15 to 39 with germ cell, Hodgkin and non ‐Hodgkin lymphoma, acute lymphoblastic leukemia, and sarcoma from Surveillance, Epidemiology, and End Results cancer registries into the first multicenter popula...
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Tags: AYA ONCOLOGY: REVIEW Source Type: research
Background: Hodgkin's lymphoma (HL) is one of the most common cancers in adolescents and young adults (AYA). Unlike acute lymphoblastic leukemia, few studies have compared AYA HL outcomes between pediatric and adult centers, or pediatric and adult protocols. Recently, a comparison of AYA (17-21 years) treated on a pediatric COG trial vs. an adult ECOG trial demonstrated superior survival in AYA treated on the pediatric trial, but other studies have not demonstrated a treatment center disparity. None of these studies were population-based. We therefore compared treatment patterns, intensity, and outcomes between AYA HL trea...
Source: Blood - Category: Hematology Authors: Tags: 902. Health Services Research-Malignant Diseases: Population Studies, End-of-life, and Palliative Care Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Brain | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Children | Genetics | Hematology | Laboratory Medicine | Leukemia | Lymphoma | Neurology | Nurses | Nursing | Psychology | Transplants